Literature DB >> 16944160

Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases.

Hayriye Sayarlioglu1, Reha Erkoc, Mehmet Sayarlioglu, Ekrem Dogan, Yasemin Soyoral.   

Abstract

Secondary amyloidosis is a well-known complication of certain familial Mediterranean fever (FMF). We presented three Turkish patients with FMF and biopsy proven amyloidosis. These patients were treated with colchicine 1.5 mg/day. They have experienced five to six peritonitis attacks with fever within 1 year. On admission, the laboratory test results were as follows: serum creatinine 2.3, 0.6, and 0.5 mg/dl; albumin 4.2, 1.9, and 1.8 g/dl; and urinary protein excretion 4, 15, and 10 g/day, respectively. All the patients were started azathioprine (AZA) 100 mg/day and attacks were completely stopped. Laboratory findings were as follows after 1 year of AZA treatment: serum creatinine 1, 0.8, and 0.6 mg/dl; albumin 4.3, 3, and 3.5 g/dl; and urinary protein excretion 3, 8, and 1.5 g/day, respectively. Treatment with azathioprine in addition to colchicine could ameliorate the nephrotic syndrome and control the attacks very effectively in these cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944160     DOI: 10.1007/s00296-006-0188-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  8 in total

1.  The coexistence of familial Mediterranean fever and polyarteritis nodosa; report of a case.

Authors:  H Koçak; N Cakar; B Hekimoglu; C Atakan; N Akkök; S Unal
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

2.  Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years.

Authors:  E Ben-Chetrit; M Levy
Journal:  Semin Arthritis Rheum       Date:  1991-02       Impact factor: 5.532

3.  Rapidly progressed secondary amyloidosis in a patient with mixed connective tissue disease.

Authors:  Hirotaka Kimura; Atsushi Komatsuda; Ken-ichi Sawada; Akio Mimori; Satoshi Baba; Seiji Minota
Journal:  Intern Med       Date:  2004-09       Impact factor: 1.271

4.  [Amyloidosis in familial mediterranean fever: clinical and renal-biopsy features (author's transl)].

Authors:  H Brass; H Klein; H Buss; H Lapp; R Heintz; B Angelkort
Journal:  Dtsch Med Wochenschr       Date:  1976-02-06       Impact factor: 0.628

Review 5.  Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report.

Authors:  D L Shapiro; H Spiera
Journal:  Arthritis Rheum       Date:  1995-12

6.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

7.  Colchicine-induced myopathy in a teenager with familial Mediterranean fever.

Authors:  Mehmet Sayarlioglu; Hayriye Sayarlioglu; Suleyman Ozen; Reha Erkoc; Ahmet Gul
Journal:  Ann Pharmacother       Date:  2003-12       Impact factor: 3.154

Review 8.  [Reversible nephrotic syndrome in Crohn's disease complicated with renal amyloidosis].

Authors:  L Larvol; J P Cervoni; M Besnier; L Dupouet; H Beaufils; J P Clauvel; H Levecq
Journal:  Gastroenterol Clin Biol       Date:  1998 Jun-Jul
  8 in total
  4 in total

Review 1.  Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up.

Authors:  Z Birsin Özçakar; Selçuk Yüksel; Mesiha Ekim; Fatoş Yalçınkaya
Journal:  Clin Rheumatol       Date:  2012-06-07       Impact factor: 2.980

2.  PREDICT: a method for inferring novel drug indications with application to personalized medicine.

Authors:  Assaf Gottlieb; Gideon Y Stein; Eytan Ruppin; Roded Sharan
Journal:  Mol Syst Biol       Date:  2011-06-07       Impact factor: 11.429

3.  Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Authors:  Sinem Nihal Esatoglu; Gulen Hatemi; Serdal Ugurlu; Aycan Gokturk; Koray Tascilar; Huri Ozdogan
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF.

Authors:  Sedat Yılmaz; Emre Tekgöz; Muhammet Çınar
Journal:  Eur J Rheumatol       Date:  2018-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.